Selventa is pioneering the analysis of Big Data to unravel the complexity of disease for precision medicine.
Selventa’s System Diagnostics (SysDxTM) platform holistically analyzes multiple types of Big Data for actionable insights; SysDx insights will be offered as a diagnostic test commercialized under the brand name ClarifyTM. Clarify line of tests enable physicians to make treatment decisions that are predictive and precise.
Selventa’s lead product is ClarifyRATM. ClarifyRA is a decision support tool for physicians to make better treatment decisions for their rheumatoid arthritis (RA) patients. The test will help match individual RA patients with the most efficacious therapy based on their personal molecular profile.
Founded in 2002 and privately held, Selventa has successfully engaged in over 110 pharmaceutical and life science consulting projects over the past 10 years and is organically profitable. During this time, Selventa has refined and validated its SysDx platform to initiate its own internal research efforts in immune-related diseases and oncology to develop a Clarify line or products. With its strong IP position and solid pharmaceutical partnerships, Selventa is well positioned to capitalize on the transforming healthcare industry and leverage cumulative Big Data information to further advance precision medicine through Clarify tests. In 2013, Frost & Sullivan recognized Selventa with a North American Technology Leadership Award for SysDx.